Development
Novartis AG
NVS
$118.08
$1.241.06%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 45.44B | 44.59B | 43.30B | 42.63B | 42.21B |
| Total Other Revenue | 1.22B | 1.26B | 1.24B | 1.23B | 1.26B |
| Total Revenue | 46.66B | 45.85B | 44.54B | 43.86B | 43.46B |
| Cost of Revenue | 12.02B | 11.79B | 11.57B | 11.27B | 11.30B |
| Gross Profit | 34.64B | 34.06B | 32.97B | 32.59B | 32.16B |
| SG&A Expenses | 12.49B | 12.18B | 12.02B | 12.03B | 12.14B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 498.00M | -846.00M | -444.00M | 373.00M | 387.00M |
| Total Operating Expenses | 34.02B | 31.33B | 31.54B | 32.21B | 32.25B |
| Operating Income | 12.64B | 14.52B | 13.00B | 11.65B | 11.21B |
| Income Before Tax | 9.12B | 8.32B | 8.35B | 7.25B | 7.18B |
| Income Tax Expenses | 551.00M | 1.07B | 1.28B | 1.12B | 1.13B |
| Earnings from Continuing Operations | 8.57K | 7.25K | 7.07K | 6.12K | 6.05K |
| Earnings from Discontinued Operations | 6.09B | 401.00M | 396.00M | 396.00M | 396.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -4.00M | -4.00M | -4.00M | -4.00M | 0.00 |
| Net Income | 14.85B | 7.84B | 7.65B | 7.03B | 6.96B |
| EBIT | 12.64B | 14.52B | 13.00B | 11.65B | 11.21B |
| EBITDA | 17.52B | 19.53B | 17.95B | 16.53B | 15.94B |
| EPS Basic | 7.19 | 3.74 | 3.61 | 3.27 | 3.19 |
| Normalized Basic EPS | 3.67 | 4.15 | 3.65 | 3.21 | 3.02 |
| EPS Diluted | 7.14 | 3.73 | 3.60 | 3.26 | 3.17 |
| Normalized Diluted EPS | 3.65 | 4.12 | 3.62 | 3.19 | 3.00 |
| Average Basic Shares Outstanding | 8.32B | 8.45B | 8.55B | 8.67B | 8.78B |
| Average Diluted Shares Outstanding | 8.37B | 8.50B | 8.61B | 8.72B | 8.84B |
| Dividend Per Share | 3.92 | 3.46 | 3.46 | 3.46 | 3.46 |
| Payout Ratio | 48.86% | 92.59% | 94.86% | 103.26% | 107.92% |